The FDA last week approved...

...AbbVIe's Rinvoq, the company's Humira successor that analysts are already speculating could reach blockbuster status, for the treatment of rheumatoid arthritis. Rinvoq's list price is $59,000. The Humira pen is still one of the most advantaged rheumatoid arthritis therapies, holding preferred status in the pharmacy benefit for 10% of covered lives, growing to 62% with step therapy and/or prior authorization, but sales have dropped as the market has become more competitive.

SOURCE: MMIT Analytics, as of 8/20/19